natgillin/translations-raw huggingface dataset:
ethyl substituted with i) phenyl, said phenyl is optionally substituted with halo or methoxy, or ii) heteroaryl; 
– etil, supstituiran s i) fenilom, gdje navedeni fenil može biti supstituiran s halogenom ili metoksi, ili ii) heteroarilom;
The method according to claim 9 or 10, wherein the neo-epitopes or epitopes are in their natural sequence context so as to form a vaccine sequence, wherein, optionally, the vaccine sequence is about 30 amino acids long. 
Individualizirano cjepivo protiv raka za uporabu prema patentnim zahtjevima 7 ili 8, naznačeno time, što su epitopi u svom prirodnom sekvencijskom kontekstu tako da formiraju sekvencu cjepiva, pri čemu sekvenca cjepiva poželjno uključuje 20 ili više amino-kiselina.
Furthermore, in mixing member 1, the mechanical force F pressing wedge-shaped transverse edges 8 a of scrapers 8 against the cylindrical inner surface of bowl 2 increases alongside the consistency and hardness of the ice-cream accumulated upstream from scrapers 8, so that mixing member 1 provides for thoroughly cleaning the lateral wall of bowl 2 even when producing ice-cream at lower than normal temperatures, i.e. below −20° C. 
Nadalje, u članku za miješanje 1, mehanička sila F koja pritiskuje klinasto oblikovane poprečne bridove 8a strugača 8 prema cilindričnoj unutarnjoj plohi zdjele 2 se povećava zajedno s konzistencijom 1 tvrdoćom sladoleda akumuliranog u kretanju prije strugača 8, tako da članak za miješanje 1 omogućuje temeljito čišćenje bočne stijenke zdjele 2, čak kod proizvodnje sladoleda na nižim od normalnih temperatura, t.j. ispod -20"C.
Example embodiments relate to a method of controlling the volumetric shrinkage of a composite material upon curing, and a method of reconstructing a tooth. 
Drugi glavni aspekti izuma odnose se na metodu kontroliranja volumetrijskog skupljanja kompozitnog materijala nakon očvršćivanja te na metodu rekonstruiranje zubi.
The processed food or feed commodity of claim 7, wherein said food or said feed commodity comprises corn meal, corn flour or corn gluten. 
Prerađena hrana ili stočna hrana prema zahtjevu 8, pri čemu spomenuta hrana ili stočna hrana obuhvaća kukuruznu krupicu, kukuruzno brašno ili kukuruzni gluten.
The pipe coupling according to claim 3, wherein the segments of the gripping means are secured to the sealing means. 
Spojnica za cijevi prema zahtjevu 3, naznačena time, da su navedeni segmenti (17) na pomagalu za stezanje (13) pričvršćeni na pomagalo za brtvljenje (12).
A compound having a structure represented by formula (II) wherein 
Tvar koja ima strukturu predstavljenu formulom (II) [image] gdje n je 0, 1, ili 2;
the surface of said body of permanent-magnetic material carries the indicia in the form of engravings, causing perturbations of its magnetic field, and 
- > navedena površina navedenog tijela nosi oznaku u obliku gravura, koje uzrokuju perturbacije magnetskog polja tijela, 1
is a nucleoside sugar group; 
R* jest nukleozidna šećerna skupina;
The method of claim 1, wherein the first nuclease agent, the second nuclease agent, or the third nuclease agent comprises an expression construct comprising a nucleic acid sequence encoding the nuclease agent, wherein the nucleic acid sequence encoding the nuclease agent is operably linked to a promoter active in the cell. The method of claim 1, wherein the first nuclease agent is: 
Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvo sredstvo nukleaze, drugo sredstvo nukleaze, ili treće sredstvo nukleaze: sadrži polinukleotid koji kodira sredstvo nukleaze, pri čemu je polinukleotid sadržan u kaseti ekspresije i operativno je povezan sa kondicionalnim promotorom, inducibilnim promotorom, konstitutivnim promotorom, ili tkivno-specifičnim promotorom;
is hydrogen or C1-C4 alkyl, preferably methyl; and ethyl; the radical represents an optionally substituted azetidine, pyrrolidine, piperidine, morpholine, oxazepane, or 1,2,3,4-tetrahydroisoquinoline ring, wherein each of R6 is independently selected from the group consisting of hydrogen, halogen, C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 spirocycloalkyl, difluoromethyl, trifluoromethyl, C1-C4 alkyloxy, aryl, hetaryl, C1-C4 aryloxy or C1-C4 arylalkoxy, wherein the aryl or hetaryl group is optionally substituted with halogen, C1-C4 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl or C1-C4 alkyloxy; 
R> je odabran od vodika, halogena, ili je heterociklički prsten odabran od pirimidin-2-il, piridin-2-il ili pirazin-2-il, koji može biti supstituiran halogenom, Ci-C4 alkilom, fluormetilom, difluormetilom, trifluormetilom ili Cy-Cu alkiloksi; R'je vodik ili C,-Ca alkil; radikal predstavlja azetidin, pirolidin, piperidin, morfolin, oksazepan ili 1,2,3,4-tetrahidroizokinolin prsten koji može biti supstituiran, gdje je svaki od R* neovisno odabran iz skupine koju čine vodik, halogen, C;-C4 alkil, Cs-Cg cikloalkil, C3-Cg spirocikloalkil, difluormetil, trifluormetil, C;-Ca alkiloksi, aril, heteroaril, C;-C4 ariloksi ili Ci-Ca arilalkoksi gdje arilna skupina ili heteroarilna skupina može biti supstituirana halogenom, C;-Cu alkilom, fluormetilom, difluormetilom, trifluormetilom ili C,-C, alkiloksi.
A supercentrifuge according to claim 4, characterized in that the valve is open when the piston is at the start of its outward travel and is provided with a spring which causes it to close when the piston is driven by the pressurised fluid to discharge the solids. 
Supercentrifuga prema zahtjevu 1, 2 ili 3, naznačena time da je ventil otvoren kada je klip na početku njegovog kretanja prema van i predviđen je s oprugom koja uzrokuje da se ventil zatvara kada je klip pogonjen sa stlačenim fluidom radi ispuštanja krutih tvari.
Furthermore, magnesium stearate can be also comprised in the dry powder preparation of the present invention preferably in an amount of 0.5-2 more preferably 1 mg per 100 mg of dry powder preparation. 
Dodatno, pripravak suhog praha predmetnog izuma može također sadržavati magnezijev stcarat poželjno u količini od 0,5 - 2, još poželjnije 1 mg po 100 mg pripravka suhog praha.
On a vibration transporting table of BKG Bruckmann & Kreyenborg Granuliertechnik GmbH, the amorphous pellets were converted into crystallized pellets. 
Na vibracijskom transportnom stolu BKG Bruckmann & Kreyenborg Granuliertechnik GmbH amorfne se pelete konvertiraju u kristalizirane pelete.
providing a modified capsular saccharide according to claim 8, part a); and 
(a) osiguravanje modificiranog saharida iz kapsule u skladu s patentnim zahtjevom 8, dio a); 1
The apparatus according to embodiment 16, wherein the neighborhood comprises at least one position horizontally adjacent to the position of the syntax element. 
Protok podataka prema zahtjevu 16, naznačen time, da se blok koeficijenata transformacije odnosi na sadržaj duboke mape.
LA is an unbranched or branched, linear saturated or partially unsaturated hydrocarbon chain having 1, 2, 3 4, 5 or 6 C atoms, wherein 1, 2 or 3H atoms may be replaced by Hal or OH; 
LA je nerazgranati ili razgranati, ravni zasićeni ili djelomično nezasićeni lanac ugljikovodika koji ima 1, 2, 3 4, 5 ili 6 C atoma, pri čemu 1, 2 ili 3 H atoma mogu biti zamijenjeni s Hal ili OH;
The best fixation of copper is achieved when copper (II) suphate pent-hydrate (CuSO4x5H2O) is used as a copper salt. 
Najbolja fiksacija bakra se postiže kad se upotrebljava bakar (II) sulfat penta-hidrat (CuSO,x5H,0) kao bakrena sol.
a human induced pluripotent stem (iPS) cell; 
ljudski izazvana pluripotentna matična ćelija;
For the purposes of the present application: 
Datum objave europske prijave patenta:
In some methods, if the synthetic retinal derivative is a 9-cis-retinyl ester comprising a monocarboxylic acid ester substituent, it is a 9-cis-retinyl C1 to C10 ester. 
Derivat retinala za upotrebu u skladu s patentnim zahtjevom 2, naznačen time, da je to 9-cis-retinil ester C3-Cx2 polikarboksilata,
The compound of claim 6, wherein R41 is selected from the group consisting of —H, lower alkyl, lower alkoxy, lower cycloalkyl, and lower cycloalkoxy. 
Spoj prema zahtjevu 19, pri čemu je R, izabran iz skupine koju čine -H, niži alkil, niži alkoksi, niži cikloalkil i niži cikloalkoksi.
The pharmaceutical according to claim 6, wherein the active substances are presented in fixed or free combination for simultaneous, sequential or separate administration together with acceptable excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application. 
Farmaceutski proizvod sukladno bilo kojem od patentnih zahtjeva 5 do 7, naznačen time, da je djelatna tvar nazočna u fiksiranoj ili slobodnoj kombinaciji za istovremeno, povremeno ili odvojeno davanje zajedno s uobičajenim ekscipijensima, adjunktima i aditivima u farmaceutskom obliku prikladnome za inhalatornu primjenu.
The compound of any one of claims 1-7 or a pharmaceutically acceptable salt thereof, wherein R1 and R1 are independently hydrogen; methyl; t-butyl; trifluoromethyl; methoxy; ethoxy; trifluoromethoxy; difluoromethoxy; fluoro; chloro; cyano; dimethylamino; methylsulfonyl; dimethylphosphoryl; tetrazolyl; pyrrolyl; phenyl unsubstituted or substituted by methyl; or piperidinyl. 
Spoj prema bilo kojem od zahtjeva 1-7 ili njegova farmaceutski prihvatljiva sol, naznačen/a time, da su R1 i R1’ neovisno vodik; metil; t-butil; trifluorometil; metoksi; etoksi; trifluorometoksi; difluorometoksi; fluoro; kloro; cijano; dimetilamino; metilsulfonil; dimetilfosforil; tetrazolil; pirolil; fenil nesupstituiran ili supstituiran s metilom; ili piperidinil.
The succinate salt as claimed in claim 1, which is in crystalline form. The succinate salt as claimed in claim 3, in crystalline form, which has an X-ray powder diffraction pattern with at least three specific peaks at about 2-theta = 6.5°, 17.7° and 14.7°. 
Mono-HCl sol spoja formule (I), prema patentnom zahtjevu 3, u kristalnom obliku koji ima obrazac rentgenske difrakcije praha sa najmanje dva specifična pika na 2-teta = 12.3° i 13.9° sa greškom mjerenja za svaki difrakcijski kut koji je plus ili minus 0.2°.
A conjugate for use in medicine, the conjugate comprising an L-asparaginase from Erwinia chrysanthemi having at least 90% identity to the amino acid sequence of SEQ ID NO:1 and polyethylene glycol (PEG), wherein the PEG has a molecular weight less than or equal to about 5000 Da. 
Konjugat za upotrebu u medicini, pri čemu konjugat sadrži I,-asparaginazu iz Erwinia chrysanthemi koja je barem 90% identična aminokiselinskoj sekvenci SEQ ID NO: 1 i polietilen glikol (PEG), naznačen time da PEG ima molekularnu masu manju ili jednaku oko 5000 Da.
The method of claim 1, wherein 1 gram of the solution comprising factor VIII in step a) comprises the following composition, the balance being water for injection: Factor VIII ≥99 IU to ≤101 IU 
Postupak prema jednom od patentnih zahtjeva 1 do 9, naznačen time što otopina koja sadrži faktor VIII u koraku a) ima sljedeći sastav u odnosu na 1 gram otopine, a ravnotežu čini voda za injekcije:
the second register node (CDNR2, DNLR1) is configured to store the network-related data or the address of the first register node (CDNR1, DNDR1), associated with the hash value, in its hash table. 
- < drugo registarsko čvorište (CDNR2, DNLRI1) je konfigurirano da pohrani mrežno povezane podatke ili adresu prvog registarskog čvorišta (CDNRI, DNDRI1), povezanog sa hash vrijednošću, u svojoj hash tablici.
The method of claim 9, wherein the target sequence of the target DNA is 15 nucleotides (nt) to 25 nt long. 
segment koji cilja na DNA, koji sadrži nukleotidni slijed komplementaran ciljanom slijedu u ciljanoj DNA, i
wherein said antibody is suitable for administering in an effective amount of about 0.001-50 mg/kilogram of said cells, tissue, organ or animal; 
(a) pri čemu je spomenuto antitijelo pogodno za primjenu u efektivnoj količini od 0,001-50 mg/kilogram na spomenutim stanicama, tkivu, organu ili životinji;
The method according to clause 3 or 4, further comprising the step of providing said insulating layer as a multi-layer structure comprising an inner layer of acoustic damping material and/or fire resistant material, optionally heat insulation material, and an outer layer, preferably of gypsum board. 
Postupak sukladno zahtjevu 3 ili 4, nadalje sadrži korak pružanja navedenog sloja izolacije (45,50) kao višeslojne strukture koja sadrži unutarnji sloj materijala akustičnog prigušivača (45) i/ili vatrootpornog materijala, opcionalno materijala koji je izolator topline, i vanjski sloj, poželjno od gips ploča (43).
ii) an amino acid sequence which has at least 86 % identity to the sequence defined in i), wherein the polypeptide binds to C5; 
i ii) aminokiselinske sekvence koja ima najmanje 86 % istovjetnosti sa sekvencom opisanom u i), pri čemu se polipeptid veže za C5;
means (r700) for receiving the digital video broadcasting signal; means (r702) for demodulating the received digital video broadcasting signal by use of an Orthogonal Frequency Division Multiplexing, OFDM, method; means (r708) for obtaining a signal frame from the demodulated digital video broadcasting signal, wherein the signal frame comprises preamble data symbols and service data symbols, wherein the preamble data symbols are divided into blocks of equal bandwidth, and wherein a bandwidth of a data slice does not exceed a bandwidth of each block; 
Kabelski prijamnik za primanje emitiranog digitalnog video signala, kabelski prijamnik obuhvaća: sredstvo (1700) za primanje emitiranog signala; sredstvo (1702) za demoduliranje primljenog emitiranog signala uporabom ortogonalne modulacijske metode u frekvencijskoj domeni, OFDM; sredstvo (1708) za dobivanje okvira signala iz demoduliranog emitiranog signala, pri čemu okvir signala obuhvaća simbole podataka početnog niza i simbole servisnih podataka;
The biologically active protein according to any one of claims 1 to 7, wherein said polypeptide with biological activity is selected from the group consisting of granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, tumor necrosis factor, erythropoietin, coagulation factor VIII, gp120/gp160, soluble tumor necrosis factor I and II receptor, reteplase, exendin-4, anakinra, interleukin-2 and neutrophil gelatinase-associated lipocalin. 
Biološki aktivni protein u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se navedeni polipeptid s biološkom aktivnošću bira iz skupine koju čine čimbenik stimulacije kolonija granulocita, ljudski hormon rasta, a-interferon, B-interferon, Y-interferon, čimbenik tumorske nekroze, eritropoetin, čimbenik zgršavanja krvi VIII, gp120/gp160, receptor topivog čimbenika tumorske nekroze I i II, reteplaza, eksendin-4, anakinra, interleukin-2 i lipokalin povezan s gelatinazom iz neutrofila.
The pharmaceutical composition for use according to claim 21, wherein the myeloproliferative disorder is polycythemia vera (PV). 
Spoj ili sol za upotrebu prema patentnom zahtjevu 16, naznačen time da je navedeni mijeloproliferativni poremećaj policitemija vera (PV).
X6, for each occurrence, is independently CH, CR9, N, N(O), N+(R17), provided that at least three X6 groups are independently selected from CH and CR9; 
S pri čemu, XÂ« je u svakom slučaju nezavisno CH, CRo, N, N(O), N'(R;.), pod uvjetom da su barem tri X4 skupine nezavisno izabrane od CH i CRy;
The process as claimed in claim 1, wherein the duration of reaction in Step (v) 24 hours to 26 hours. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je trajanje reakcije u Koraku (v) 24 sata do 26 sati.
Even if a would-be thief were to pick the key-cut combination of the key, he still would not defeat the lock without additionally aligning the movable element with the auxiliary locking pin. 
Čak i kada bi potencijalni lopov imao kombinaciju ureza ključa, ne bi mogao otvoriti bravu bez dodatnog poravnavanja pokretnog elementa sa sporednim zaustavnim trnom.
The manufacture of a batch of at least 50 vials of each of these formulations is described. 
Opisana je proizvodnja grupe od najmanje 50 ampula svakog od ovih oblika.
is hydrogen or lower alkyl, unsubstituted or substituted with halogen; and n is 0, 1, 2 or 3; 
je vodik ili C1-C7-alkil, nesupstituiran ili supstituiran s halogenom; i njegove farmaceutski podnošljive soli.
decarboxylating a compound of Formula 3, or a salt thereof, or hydrolyzing and decarboxylating the compound of Formula 3 or a salt thereof, to yield a compound of Formula 8, or a salt thereof; reducing a cyano moiety of the compound of Formula 8 or a salt thereof, to yield the compound of Formula 1 or a salt thereof; and optionally converting the compound of Formula 1 or a salt thereof into a pharmaceutically acceptable complex, salt, solvate or hydrate, wherein 
(a) dekarboksiliranju spoja Formule 3 ili njegove soli, ili hidrolizi i dekarboksiliranju spoja Formule 3, ili njegove soli, kako bi se dobilo spoj Formule 8 HR P20100054 TI ili njegovu sol; (c) izbornom prevođenju spoja Formule 1, ili njegove soli, u njegov farmaceutski prihvatljiv kompleks, sol, solvat ili hidrat, gdje svaki od R! i R* u Formuli 3 i Formuli 8 je definiran kao za Formulu 1;
2 in part (a) a plane view of a blank for the outer shell of the package according to FIG. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 23, naznačen time što su vanjska ljuska (2; 92;
A pharmaceutical composition comprising: the hemitartrate salt of a compound represented by the following structural formula: 
Prvo terapijsko sredstvo predstavljeno sa slijedećom strukturnom formulom: O
Compounds according to claim 1 wherein: represents wherein R9 is as defined in claim 1. 
[image] predstavlja [image] pri čemu je R9, kako je definirano u patentnom zahtjevu 1.
The composition according to claim 8 wherein the beta-carotene is present in an amount of 0.1 mg to 5 mg. 
Pripravak u skladu sa zahtjevom 8 naznačen time da je beta-karoten prisutan u količini od 0.1 mg do 5 mg.
wherein said FTI is administered for at least 3 cycles or for at least 6 cycles. 
Spoj za uporabu u skladu s patentnim zahtjevom 9, pri čemu je tipifarnib primjenjivan barem 3 ciklusa ili barem 6 ciklusa.
The method of claim 1, wherein the method is applied when the portion of water is actually used for recreational purposes. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što postupak se primjenjuje kada se dio vode stvarno koristi za rekreaciju.
Therefore, transformation triggered by slow mechanisms, e.g., diffusion of water into the cured compound can happen after the curing. 
Stoga je transformacija potaknuta polaganim mehanizmom, npr. difuzija vode u čvrsti spoj se može odvijati nakon očvršćivanja.
The therapeutic hosiery item according to one or more of the preceding claims, characterized in that said first rows of knitting (1) are composed of a double-coated elastomer yarn (1a). 
Terapeutska čarapa prema jednom ili više prethodnih zahtjeva, naznačena time, da su spomenuti neparni redovi pletiva (1) izrađeni od najmanje jednog dvostruko prevučenog elastomernog konca (1a).
The process according to claim 2, comprising the following operations: 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što se sastoji sljedećim radnjama:
The chimeric protein according to any one of claims 2 to 6, wherein said heterologous polypeptide comprises or consists of, from N-terminal to C terminal, the C-terminal part of the E7 protein of a first HPV type, the C-terminal part of the E7 protein of a second HPV type, the C-terminal part of the E7 protein of a third HPV type, optionally the C-terminal part of the E7 protein of a fourth HPV type, the N-terminal part of the E7 protein of said first HPV type, the N-terminal part of the E7 protein of said second HPV type, the N-terminal part of the E7 protein of said third HPV type, and optionally the N-terminal part of the E7 protein of said fourth HPV type. 
Kimerni protein u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, naznačen time što navedeni heterologni polipeptid sadrži ili se sastoji od, od N-kraja do C-kraja, C-terminalnog dijela proteina E7 iz prvog tipa HPV-a, C-terminalnog dijela proteina E7 iz drugog tipa HPV-a, C-terminalnog dijela proteina E7 iz trećeg tipa HPV-a, izborno C-terminalnog dijela proteina E7 iz četvrtog tipa HPV-a, N-terminalnog dijela proteina E7 iz navedenog prvog tipa HPV-a, N-terminalnog dijela proteina E7 iz navedenog drugog tipa HPV-a, N-terminalnog dijela proteina E7 iz navedenog trećeg tipa HPV-a, te izborno N-terminalnog dijela proteina E7 iz navedenog četvrtog tipa HPV-a.
The method of claim 13 or 15, wherein said biological sample is selected from corn meal, corn oil, corn cake, corn seed, corn germ, corn starch, corn flour, corn pollen, corn silk, corn steep liquor, corn malt, corn sugar, corn syrup, margarine produced from corn oil, distillers dry goods solids (DDGS), cosmetic and bulking agent. 
Postupak prema zahtjevu 13 ili 15, pri čemu je navedeni biološki uzorak odabran između kukuruznog brašna, kukuruznog ulja, kukuruznih kolača, sjemena kukuruza, klica kukuruza, kukuruznog škroba, kukuruzne peludi, kukuruzne svile, tekućine od namakanja kukuruza, kukuruzne sladi, kukuruznog šećera, kukuruznog sirupa, margarina proizvedenog od kukuruznog ulja, sušenih krutih tvari, kozmetičkih sredstava i sredstava za bubrenje.
In a preferred embodiment, the plasma profile achieved by the method of the present invention may be described as follows: the mean plasma buprenorphine concentration after initial titration administration with a two 20 mg buprenorphine patches, which results in approximately 800 pg/ml. 
U preferiranom uobličenju, profil u plazmi postignut metodom ovog izuma može se opisati kao što slijedi: srednja koncentracija buprenorfina u plazmi nakon početnog titracijskog davanja pomoću dva flastera s 20 mg buprenorfina, što rezultira s približno 800 pg/ml.
The aqueous pharmaceutical suspension according to claim 3, wherein the sweetener system comprises, by weight/volume (g/100 mL), 0% to 20% of xylitol, and 10% to 40% of sucrose. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što sustav sladila sadrži, težinski/volumno (g/100 ml), 0 % do otprilike 20 % ksilitola, te otprilike 10 % do otprilike 40 % saharoze.
is selected from alkyl, hydroxy or cycloalkyl; 
R; je odabran iz alkila, hidroksija ili cikloalkila;
A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R3 is methyl and the stereocentre produced has the (R)-configuration. 
Spoj u skladu s patentnim zahtjevom 8, ili njegova farmaceutski prihvatljiva sol, naznačen time, da R3 je metal, a dobiveni stereocentar ima (R)-konfiguraciju.
Compounds of the present invention may be prepared by procedures illustrated in the accompanying schemes. 
Spojevi prikazanog izuma mogu se pripremiti postupcima koji su prikazani na popratnim prikazima.